ReviewInternational journal of obesity (2005)2026
The role of SIRT4 in obesity: from molecular mechanisms to clinical implications.
Review in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sirtuin 4 Knockout Aggravates Sepsis-Induced Acute Liver Injury by Enhancing Mitochondrial Fission and Mitophagy in Hepatocytes.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has emerged as a pervasive global public health issue, and the etiology of obesity is now understood to be increasingly intricate and multifactorial, encompassing genetic predispositions, sedentary lifestyles coupled with excessive caloric intake, as well as environmental and social interactions. Recent studies have indicated a close association between SIRT4 and obesity. The pathophysiological mechanisms underlying its influence on obesity predominantly involve four interconnected pathways: fatty acid oxidation, adipocyte differentiation, insulin secretion, and inflammation. Furthermore, emerging studies are exploring the clinical translational potential of SIRT4. As a mitochondria-localized member of the sirtuin family, SIRT4 possesses both deacetylase and ADP-ribosyltransferase enzymatic activities. This mitochondrial enzyme is involved in metabolic regulation through modulating energy homeostasis and lipid metabolic processes, inflammatory signaling pathways, neuroendocrine regulatory networks, and the epigenetics of adipocyte differentiation. However, the lack of comprehensive synthesis and critical evaluation of existing evidence has left the precise relationship between SIRT4 and obesity incompletely understood. Therefore, this review systematically synthesizes current knowledge regarding SIRT4's mechanistic involvement in obesity development, while evaluating clinical correlations and regulatory strategies. This review focuses on the potential of SIRT4 in the regulation of obesity and the progress in related studies. The search criteria encompass keywords related to the role of SIRT4 in physiological and biochemical processes such as lipid and energy metabolism, adipocyte differentiation, as well as its clinical applications, with a total of 63 references cited.
Indexed as
Identifiers
41233560What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.